Mitral Valve Replacement Indications

Primary Mitral Regurgitation

The American College of Cardiology recommends mitral valve surgery for symptomatic patients with severe primary mitral regurgitation and left ventricular ejection fraction (LVEF) >30% 1, 2, 3
Symptoms of severe primary mitral regurgitation include decreased exercise tolerance, exertional dyspnea, or heart failure, with severe MR defined by vena contracta ≥0.7 cm, regurgitant volume ≥60 mL, regurgitant fraction ≥50%, or effective regurgitant orifice (ERO) ≥0.40 cm² 1, 4, 5
The American College of Cardiology suggests surgery is required for asymptomatic patients with severe primary mitral regurgitation and LVEF 30-60% and/or left ventricular end-systolic diameter (LVESD) ≥40 mm to prevent irreversible ventricular damage and improve long-term survival 1, 2, 3, 6
Mitral valve repair is strongly preferred over replacement when primary mitral regurgitation is limited to the posterior leaflet or when a successful, durable repair can be accomplished for anterior leaflet or both leaflets involvement 1, 2, 3, 6

The European Society of Cardiology indicates that surgery is indicated for patients with severe secondary mitral regurgitation undergoing coronary artery bypass grafting (CABG) when LVEF >30% 7, 8
The American College of Cardiology suggests that isolated mitral valve surgery may be considered in patients with severe secondary mitral regurgitation and LVEF >30% who remain symptomatic despite optimal medical management and have low surgical risk 7, 8
The European Society of Cardiology recommends reassessing the severity of secondary mitral regurgitation after optimized medical treatment before making surgical decisions, with optimal heart failure therapy including ACE inhibitors, beta-blockers, and mineralocorticoid receptor antagonists 7, 8, 9

The American College of Cardiology advises against delaying surgery in symptomatic severe primary mitral regurgitation with preserved LVEF, as waiting for symptoms to worsen or LVEF to decline results in irreversible ventricular damage and worse outcomes 1, 2, 3
The European Society of Cardiology cautions against performing isolated mitral surgery for secondary mitral regurgitation without first optimizing medical therapy, including cardiac resynchronization therapy if indicated, as there is no proven survival benefit from isolated valve intervention 7, 8

The American College of Cardiology recommends that all patients with secondary mitral regurgitation (MR) must receive optimal guideline-directed medical therapy (GDMT) before any consideration of valve intervention, with a Class I recommendation for ACE inhibitors or ARBs, beta-blockers, and aldosterone antagonists 10, 11, 12
The American College of Cardiology also recommends cardiac resynchronization therapy (CRT) if the patient meets device indications, as part of optimal GDMT 10, 11, 12

The American Heart Association suggests that mitral valve surgery is reasonable when patients with severe secondary MR are already undergoing coronary artery bypass grafting (CABG) or other cardiac surgery, particularly if left ventricular ejection fraction (LVEF) is >30%, with a Class IIa recommendation 11, 13
The American College of Cardiology indicates that isolated mitral valve repair or replacement may be considered for severely symptomatic patients (NYHA class III-IV) with chronic severe secondary MR who have persistent symptoms despite optimal GDMT, with a Class IIb recommendation 10, 11, 12

The American Heart Association notes that for secondary MR, the choice between repair and replacement remains controversial, with no clear survival advantage for either approach 11

The European Society of Cardiology and the American College of Cardiology caution against performing isolated mitral surgery for secondary MR without first optimizing medical therapy, as there is no proven survival benefit from isolated valve intervention 10, 11
It is essential to recognize that secondary MR has fundamentally different pathophysiology compared to primary MR, and the surgical indications are much weaker for secondary disease 10, 11

The European Heart Journal suggests that for patients who are not surgical candidates, transcatheter edge-to-edge repair (TEER) may be considered in appropriately selected patients with severe secondary MR and appropriate anatomy 13